NEJM publishes final results of Radixivir global trial showing three important benefits

With the development of the global epidemic, Redsiway has received sustained attention from the industry and the general public.
comes after preliminary results from a global clinical trial called ACTT-1 sponsored by the American Institute of Allergy and Infectious Diseases (NIAID) showed that Redsyvir significantly accelerated the recovery time of patients hospitalized with neo-coronavirus disease (COVID-19).
October 8, the final report of the ACTT-1 trial was published in the New England Journal of Medicine (NEJM), helping us to better understand the effects of the drug on COVID-19 patients.
"The final report provides new information and extends the benefits of Redsiway, and each outcome of the study is critical to managing the COVID-19 pandemic and health care provider-patient communication decisions," Daniel O'Day, chairman and chief executive officer of Gilead Sciences, said in an open letter.
" Screenshot Source: New England Journal of Medicine Let's start by reviewing the experimental design of ACTT-1.
this is an adaptive, randomized double-blind placebo-controlled global Phase 3 clinical trial.
trials began on 21 February 2020 and ended on 19 April 2020 in 73 clinical centres in several countries around the world.
patients in the group were adults hospitalized with COVID-19 confirmed by nucleic acid testing, and there was evidence of lower respiratory tract infection.
patients were randomly grouped at 1:1, and the Redsiway group received treatment for up to 10 days, with an initial dose of 200 mg, followed by 100 mg once a day;
the final report, 1,062 patients received random groupings (541 received Redsyve and 521 received a placebo).
the final data delivered three important messages: 1. Redsyve accelerates patient recovery.
the severity of the condition, the patient's effectiveness in receiving Redsyve treatment also varied.
. overall, the medium recovery time was 10 days for patients in the Redsiwe group, 15 days for patients in the placebo group, and 29 percent for patients treated with Redsyves.
patients with severe illnesses, the recovery of patients in the Redsyve group accelerated by 31% (medium recovery time of 11 days vs 18 days), which accounted for 90.1% of the total number of trials.
the study, symptoms were assessed as patients who needed hospitalization and low-flow oxygen absorption, and recovery benefited most, with a 45 percent acceleration.
patients who had been on medication earlier recovered more quickly.
recovery of patients treated with Redsyve within 10 days of onset was significantly accelerated by 37%, and recovery of patients who were on medication 10 days after onset was significantly accelerated by 20% and was not statistically significant.
, after considering the effects of glucodermal hormones or hydroxychloroquine, Redsyve still showed the efficacy of accelerating patient recovery.
2. Redsiway reduces the risk of progression.
were assessed on the basis of a sequence of 8 symptoms, patients in the Redsiwe group were 50 percent more likely to see improvement in clinical symptoms on the 15th day.
3. Throughout the study period, Redsiway showed a trend towards reducing patient mortality.
Of all the subjects, the mortality rate was 6.7 per cent on the 15th day, 11.9 per cent in the placebo group, 11.4 per cent in the Redsiway group and 15.2 per cent in the placebo group on the 29th day.
risk of death was reduced by 27% in the Redsiwe group, but was not statistically significant.
note that the risk of death in the Redsyway group was significantly reduced by 70 per cent among patients who needed hospitalization and low-flow oxygen absorption before the trial (which was also the largest category in the trial, at 40 per cent).
addition, in terms of safety, 131 (24.6%) of the 532 patients treated with Redsyve had severe adverse events and 163 (31.6%) of the 516 patients receiving placebo had serious adverse events.
Said O'Day, "For COVID-19 inpatients, we cannot underestimate the importance of accelerating recovery by 5-7 days."
"because it will not only reduce the physical challenges that COVID-19 itself poses to patients, but also reduce the risk of secondary infections that patients face as a result of prolonged hospitalization, and will also ease the emotional burden on patients and their families."
, on the other hand, reducing disease progression "avoids patients entering critical stages of disease exacerbation, as patients have a lower chance of survival once a ventilator is needed."
" and these patient benefits will also translate into savings in medical resources.
, the question of whether Redsiway could reduce COVID-19 deaths was answered, providing valuable information for clinical practice.
currently, Redsyve has been approved or authorised for COVID-19 treatment in more than 50 countries around the world.
team also noted in the discussion of the paper that the current COVID-19 mortality rate is still high, it is clear that the use of antiviral drugs alone is not enough to treat all patients.
therefore, studies will continue to assess the effects of the combined use of Redsyve with immunoresponsive regulators, such as ACTT-2 and ACTT-3 trials, which are being evaluated in the form of a joint drug with JAK inhibitor baricitinib or interferon β-1a.
, we still need multiple treatments and multiple combination drug strategies to continuously improve the prognosis of COVID-19 patients.